Company ProfilePremium

Johnson and Johnson

Company Profile Analysis

Ticker: JNJ

ESOMAR 23 Corporate BadgeISO Certifications Badge
Johnson and Johnson - Company showcase

Year Founded & Workforce

2023

140,800 Employees

Johnson and Johnson logo

Johnson and Johnson Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Johnson and Johnson Overview

Johnson & Johnson is the world's largest and most broadly diversified healthcare company, and — following the 2023 separation of its Consumer Health business and the announced separation of its Orthopaedics business — it is in the late stages of a decade-long transformation from a three-sector conglomerate into a focused, science-led enterprise operating across two segments: prescription medicines and interventional medical technology. The company's stated positioning is that of a comprehensive healthcare innovation platform capable of addressing disease across the full continuum, from pharmacological intervention to procedural and device-based treatment, with self-declared leadership ambitions concentrated in six businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. Financially, the company is defined by three characteristics that few peers share simultaneously: scale (FY2025 revenue of USD 94.2 billion, on track to exceed USD 100 billion in FY2026 for the first time in a 140-year corporate history), balance-sheet quality (one of only three U.S. corporates carrying both a Moody's Aaa and an S&P AAA long-term issuer rating), and dividend durability (64 consecutive years of dividend increases as of 2026). The structural counterweights are equally distinctive: a decade-long talc product-liability overhang now moving toward resolution, an accelerating patent-cliff sequence beginning with STELARA and extending to DARZALEX later this decade, and a MedTech segment whose margin profile has compressed materially since 2021.

Geographic distribution of the workforce as disclosed in the FY2025 annual report comprises four regions — North America, EMEA, Asia Pacific and Latin America — with shares of approximately 35.9%, 27.8%, 19.5% and 16.8%. The precise region-to-percentage mapping is not unambiguously recoverable from the extracted disclosure and should be verified against the source document before use in a client deliverable.


The company's own characterisation. In the FY2025 Form 10-K, Johnson & Johnson describes itself as a holding company whose operating subsidiaries conduct business in virtually all countries of the world, with a primary focus on products related to human health and well-being. It positions its dual-segment structure as a source of unique advantage, arguing that expertise spanning both medicines and medical technology allows it to innovate across the full spectrum of healthcare solutions. The Chief Operating Decision Maker is the Chief Executive Officer; strategy and priorities are set by a ten-member Executive Committee, within whose parameters U.S. and international operating-company management teams retain responsibility for their own strategic plans and day-to-day operations.

Independent characterisation. Johnson & Johnson is best understood not as a single business but as two structurally different businesses sharing a balance sheet, a capital-allocation function and a brand.

The Innovative Medicine segment (64.1% of FY2025 revenue) is a classical research-based biopharmaceutical operation. Its economics are those of a patent-protected specialty portfolio: gross margins well in excess of the corporate average, R&D intensity in the mid-teens as a share of segment sales, segment pre-tax margins of 36.9% in FY2025, and revenue that is highly concentrated in a small number of large molecules. Three products — DARZALEX/DARZALEX FASPRO, STELARA and TREMFYA — accounted for approximately 15.0%, 6.5% and 5.5% of total company revenue in FY2025 respectively, or roughly 27% of consolidated sales from three franchises. The revenue model is almost entirely product sales of prescription medicines distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals; there is no meaningful subscription or service component, and licensing income is disclosed as immaterial relative to product revenue. The segment carries substantial inbound royalty obligations that function economically as a revenue-sharing arrangement: Genmab A/S receives 12–20% of total DARZALEX net sales, amounting to approximately USD 2.4 billion in fiscal 2025 and USD 2.0 billion in fiscal 2024; third-party licensors receive approximately 5.0% of TREMFYA net sales.

The MedTech segment (35.9% of FY2025 revenue) is a procedural-technology business. Its economics are those of a capital-and-consumables medical device operation: lower gross margin, heavy field-force and clinical-evidence cost, higher fixed manufacturing intensity, and segment pre-tax margins of 12.2% in FY2025 — roughly one third of the Innovative Medicine level. Demand is driven by procedure volumes rather than prescription volumes, which makes the segment sensitive to hospital capital budgets, elective-procedure recovery, surgeon adoption cycles and, in China, government volume-based procurement tendering. Revenue mixes durable capital equipment (electrophysiology mapping consoles, robotic platforms, VELYS robotic-assisted surgical solutions) with high-recurrence consumables (catheters, staplers, sutures, contact lenses, intraocular lenses), producing a razor-and-blade dynamic in the fastest-growing sub-franchises.

Value chain position. The company sits at the innovation and manufacturing end of the healthcare value chain, upstream of distribution and dispensing. It operates 63 owned or leased manufacturing facilities and sources from thousands of suppliers. Concentration in the customer base is material and disclosed: in fiscal 2025 three wholesalers distributing products for both segments represented approximately 21.8%, 15.5% and 11.1% of total gross revenues — 48.4% in aggregate. The 10-K does not name these wholesalers. In fiscal 2024 the equivalent figures were 20.5%, 15.6% and 12.3%.

Customer types and end-markets. Innovative Medicine sells into retail pharmacy, hospital pharmacy, specialty distribution and government procurement channels, with reimbursement determined by government programmes (Medicare, Medicaid, national health systems), private insurers and pharmacy benefit managers. MedTech sells into hospitals, ambulatory surgical centres, eye-care professional practices and specialty clinics, with purchasing decisions made by clinicians in conjunction with hospital value-analysis committees and group purchasing organisations. End-markets served span oncology (prostate, hematologic malignancies, lung, bladder), immunology (rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis), neuroscience (mood disorders, neurodegenerative disorders, schizophrenia), pulmonary arterial hypertension, infectious disease (HIV), cardiovascular and metabolism (thrombosis, diabetes, macular degeneration), interventional cardiology and electrophysiology, orthopaedic reconstruction and trauma, general and advanced surgery, and vision correction and cataract surgery.

Revenue concentration by geography. Approximately 43% of fiscal 2025 sales occurred outside the United States: roughly 23% in Europe, 5% in the Western Hemisphere excluding the U.S., and 15% in Asia-Pacific and Africa. Four markets — Argentina, Turkey, Venezuela and Egypt — are accounted for as highly inflationary economies because three-year cumulative inflation surpassed 100%.

Strategy

Stated strategy

The company's strategic articulation, as set out in the FY2025 annual report and the 2026 proxy statement, rests on four themes.

First, portfolio concentration on six businesses. Management repeatedly frames the enterprise around Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, describing fiscal 2025 as the start of a new era of accelerated growth driven by expanding leadership in each. The corollary is exit from anything outside those six: Consumer Health in 2023, orthopaedics from 2027, and the fiscal 2023–2026 restructuring programmes that exited infectious disease and vaccine R&D, orthopaedic product lines and non-strategic surgery lines.

Second, dual-segment breadth as a differentiator. Management argues that spanning both medicines and medical technology gives the company depth and scale unavailable to single-modality competitors, positioning it to innovate across the full spectrum of healthcare solutions.

Third, scale investment in innovation, both internal and external. More than USD 32 billion was invested in fiscal 2025 across R&D and inorganic innovation, comprising the USD 14.7 billion R&D line, the Intra-Cellular and Halda acquisitions, and 40 further collaborations, partnerships and licences.

Fourth, a stated line of sight to double-digit revenue growth by the end of the decade. This is the single most consequential management claim and is reaffirmed at each earnings call. The mechanism, as articulated by the CFO and on the Q1 2026 call, is the scaling of recent launches combined with the roll-off of DARZALEX royalties in 2029.

Announced initiatives, last 24 months

DateInitiativeDetail and target
Oct 2025Orthopaedics separationStandalone DePuy Synthes; all separation vehicles under evaluation; targeted mid-2027 completion; intended to shift the MedTech portfolio toward higher-growth, higher-margin markets
2025 (ongoing)USD 55 billion U.S. investment programmeManufacturing, R&D and technology through 2029; four announced sites (Wilson NC, Holly Springs NC, plus new Pennsylvania cell therapy and North Carolina drug product facilities); further announcements expected during 2026
Jan 2026Voluntary U.S. government pricing agreementParticipation in TrumpRx; most-favoured-nation price alignment with comparable developed markets for cash-paying patients and for Medicaid; in exchange, a limited-period exemption from pharmaceutical tariffs contingent on domestic manufacturing expansion. The company is one of 15 of 17 large manufacturers to have reached such an agreement
Q2 2026Jacksonville, Florida vision manufacturingMore than USD 1 billion to strengthen U.S. vision manufacturing
Jul 2026Sail Biomedicines collaborationIn vivo CAR-T for immune-mediated disease; USD 785 million initial (including USD 465 million equity), USD 140 million contingent milestones, exclusive option to acquire for USD 2.58 billion
Jun–Jul 2026Firefly Bio acquisitionUSD 1 billion cash for the Firelink degrader antibody conjugate platform targeting pan-KRAS and other hard-to-treat solid tumour drivers
Jul 2026Talc settlementApproximately USD 5.5 billion to resolve substantially all outstanding U.S. ovarian cancer claims, conditional on 95% claimant acceptance
May–Jun 2026DePuy Synthes bolt-onsAgreement to acquire miniature radiofrequency tracking technology for joint reconstruction; exclusive U.S., Canada and Australia distribution agreement for CGBIO's NOVOSIS
2025–2026Surgery franchise restructuringExit of non-strategic product lines and site optimisation; USD 205 million pre-tax cost in fiscal 2025; substantially complete by end of fiscal 2026
Announced Q1 2026Enterprise Business ReviewScheduled for 8 December 2026 — the principal forward catalyst for medium-term guidance

Management financial targets and guidance

Guidance metricJanuary 2026April 2026July 15, 2026July 29, 2026 (post-transactions)
Estimated reported sales, midpoint (USD B)100.5100.8101.1101.1
Reported sales growth, midpoint (%)6.77.07.37.3
Operational sales, midpoint (USD B)100.0100.2100.6100.6
Adjusted operational sales growth, midpoint (%)5.96.16.56.5
Adjusted EPS, midpoint (USD)11.5311.5511.6811.04
Adjusted EPS growth, midpoint (%)6.97.18.22.3
Adjusted operational EPS, midpoint (USD)11.3811.4011.5810.94

The 29 July 2026 revision reflects USD 0.64 of dilution from the Firefly acquisition (USD 0.46) and the Sail transaction (USD 0.18). Combined 2027 dilution is guided at approximately USD 1.36 — USD 0.08 from Firefly and USD 1.28 from Sail, assuming milestone achievement and exercise of the acquisition option. Adjusted pre-tax operating margin expansion for fiscal 2026 was raised at the July update to approximately 75 basis points from at least 50 basis points. Fiscal 2026 contains a 53rd week, weighting Q4 contribution.

Sustainability metrics are integrated into executive compensation, and third-party assurance of environmental data is being expanded.

Products & Services

Twenty-eight products and platforms each generated more than USD 1 billion in annual sales in fiscal 2025, with Shockwave and CARVYKTI joining that cohort during the year.

Innovative Medicine — Oncology

Product (worldwide, USD Mn)FY2024FY2025Reported growth (%)
DARZALEX / DARZALEX FASPRO11,67014,35123.0
ERLEADA2,9993,57419.2
IMBRUVICA3,0382,823-7.1
CARVYKTI9631,88795.9
RYBREVANT / RYBREVANT FASPRO / LAZCLUZE327734—
TECVAYLI54967022.1
ZYTIGA / abiraterone acetate631502-20.4
TALVEY28746361.3
Other Oncology (incl. INLEXZO, AKEEGA)31737618.5
  • DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) — anti-CD38 monoclonal antibody for multiple myeloma; FASPRO additionally approved for light chain (AL) amyloidosis and, from Q4 2025, as the first and only FDA-approved treatment for high-risk smouldering multiple myeloma. The company's largest product at approximately 15.0% of total revenue. Compound patent families expire in the United States in 2029; European compound/use protection in selected countries extends to 2031/2032. Genmab royalty 12–20% of net sales.

ERLEADA (apalutamide): next-generation androgen receptor inhibitor for prostate cancer. A Phase 3 study reported in Q2 2026 showed significant reduction in metastasis or death when given before and after surgery in localised high-risk disease. Named on the CMS Selected Drug list for 2028 under the Inflation Reduction Act (published January 2026).

CARVYKTI (ciltacabtagene autoleucel): BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma, developed and commercialised with Legend Biotech. Described by the company as the most successful cell therapy launch to date, with more than 10,000 patients treated across 14 markets; 2.5-year data show durable treatment-free remissions with earlier-line use.

  • RYBREVANT (amivantamab) / RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) / LAZCLUZE (lazertinib) — EGFR bispecific antibody plus brain-penetrant EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer. FDA approval of the subcutaneous FASPRO formulation in combination with LAZCLUZE (Q4 2025) delivers the shortest administration time for a first-line combination regimen. Expansion data reported in colorectal and head-and-neck cancer.

TECVAYLI (teclistamab-cqyv): and TALVEY (talquetamab-tgvs) — BCMA- and GPRC5D-directed bispecific T-cell engagers for heavily pre-treated multiple myeloma. The Phase 3 MajesTEC-3 study supports TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line; TECVAYLI monotherapy demonstrated superior progression-free and overall survival as early as first relapse.

IMBRUVICA (ibrutinib): BTK inhibitor for B-cell malignancies and chronic graft-versus-host disease; co-developed and co-commercialised in the U.S. with Pharmacyclics LLC, an AbbVie company. In structural decline; included on the initial CMS Selected Drug list.

ZYTIGA (abiraterone acetate): prostate cancer; genericised and in terminal decline.

INLEXZO (gemcitabine intravesical system): drug-releasing intravesical system for BCG-unresponsive high-risk non-muscle-invasive bladder cancer, approved in 2025; reported 74% disease-free survival at one year in papillary-only NMIBC. Positioned as an alternative to cystectomy.

AKEEGA (niraparib and abiraterone acetate): approved in Q4 2025 as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer, with a 54% reduction in disease progression versus standard of care.

Innovative Medicine — Immunology

Product (worldwide, USD Mn)FY2024FY2025Reported growth (%)
STELARA10,3616,078-41.3
TREMFYA3,6705,15540.5
SIMPONI / SIMPONI ARIA2,1902,66821.8
REMICADE1,6051,76810.2
Other Immunology361—

STELARA (ustekinumab): IL-12/23 inhibitor for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. The company's second-largest product at 6.5% of total revenue, now in accelerating biosimilar erosion; it created an approximately 1,040 basis-point drag on Innovative Medicine operational growth in fiscal 2025 and 760 basis points in Q2 2026. On the initial CMS Selected Drug list, though CMS has indicated it will be removed from that list beginning in 2027.

TREMFYA (guselkumab): IL-23 inhibitor and the designated successor franchise. Third-largest product at 5.5% of total revenue; the fastest-growing IL-23 therapy in the U.S.; the first and only IL-23 inhibitor with a fully subcutaneous regimen for both ulcerative colitis and Crohn's disease; two-year Crohn's remission data reported; the only IL-23 inhibitor shown to substantially inhibit structural joint damage in active psoriatic arthritis, with an FDA label expansion granted in Q2 2026; also the first IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease. Composition patent family projected to expire in the United States in 2031; aggregate third-party royalty approximately 5.0% of net sales.

ICOTYDE (icotrokinra): approved 18 March 2026; the first and only targeted oral peptide that blocks the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and patients 12 and older weighing at least 40 kg. Phase 3 ICONIC programme in approximately 2,500 patients; taken once daily on waking, 30 minutes before food. Jointly discovered and developed under a licence and collaboration agreement with Protagonist Therapeutics. Management reported over 1,500 prescriptions written and 1,000 unique prescribers engaged within weeks of approval, and the CEO has described it as potentially one of the company's largest products ever. Supported by the ICOTYDE withMe patient access programme.

SIMPONI / SIMPONI ARIA (golimumab): subcutaneous and intravenous anti-TNF for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and polyarticular juvenile idiopathic arthritis; grew 21.8% in fiscal 2025, largely on international strength.

REMICADE (infliximab): anti-TNF for immune-mediated inflammatory diseases; returned to growth in fiscal 2025 (+10.2%) on U.S. contracting dynamics.

IMAAVY (nipocalimab-aahu): FcRn blocker approved for generalized myasthenia gravis, with more than two years of sustained disease control demonstrated in a broad gMG population and a head-to-head trial against an alternative FcRn blocker underway. FDA Priority Review granted in Q2 2026 for warm autoimmune hemolytic anemia, a disease with no currently approved therapies. Phase 2 data reported in systemic lupus erythematosus and, published in The Lancet, in Sjögren's disease.

JNJ-4804: investigational co-antibody therapy for refractory inflammatory bowel disease, with data reported in Q2 2026 in ulcerative colitis and Crohn's disease.

Innovative Medicine — Neuroscience

Product (worldwide, USD Mn)FY2024FY2025Reported growth (%)
CAPLYTA (from April 2025)0700—
CONCERTA / methylphenidate641584-8.9
Balance of Neuroscience (SPRAVATO, INVEGA family, other)6,4746,5531.2

CAPLYTA (lumateperone): acquired with Intra-Cellular Therapies; approved for schizophrenia, bipolar depression, and — in Q4 2025 — as adjunctive therapy for major depressive disorder. An sNDA for prevention of relapse in schizophrenia was approved in Q2 2026. Network meta-analysis published in Q2 2026 positioned it as showing the greatest improvement across key efficacy outcomes among adjunctive MDD treatments. Contributed 1.2 percentage points of Innovative Medicine operational growth in fiscal 2025.

SPRAVATO (esketamine): nasal spray — for treatment-resistant depression and for depressive symptoms in MDD with suicidal ideation. More than 200,000 patients treated worldwide; grew 67.8% in Q4 2025 and was cited by management as a principal Neuroscience growth driver in fiscal 2025 and H1 2026.

  • INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate) — long-acting injectable antipsychotics for schizophrenia and schizoaffective disorder.

CONCERTA (methylphenidate HCl extended-release): ADHD; in decline, with U.S. sales down 38.6% in fiscal 2025.

Innovative Medicine — Pulmonary Hypertension, Infectious Disease, Cardiovascular & Metabolism

OPSUMIT (macitentan) / OPSYNVI (macitentan and tadalafil): endothelin receptor antagonist monotherapy and fixed-dose combination for long-term treatment of pulmonary arterial hypertension.

UPTRAVI (selexipag): the only approved oral and intravenous selective IP receptor agonist targeting the prostacyclin pathway in PAH.

XARELTO (rivaroxaban): oral Factor Xa inhibitor for DVT/PE prophylaxis and treatment, stroke prevention in non-valvular atrial fibrillation, major cardiovascular event reduction in CAD and PAD, and paediatric thromboprophylaxis including post-Fontan. On the initial CMS Selected Drug list, with CMS indicating removal from 2027.

HIV portfolio: EDURANT (rilpivirine), PREZISTA (darunavir), PREZCOBIX/REZOLSTA (darunavir/cobicistat) and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single-tablet regimen.

MedTech portfolio and franchise revenue

MedTech franchise (worldwide, USD Mn)FY2024FY2025Reported growth (%)
Surgery9,84110,1383.0
Orthopaedics9,1589,2581.1
Cardiovascular7,7078,92815.8
Vision5,1465,4686.3
Total MedTech31,85733,7926.1
Cardiovascular sub-franchise (USD Mn)FY2024FY2025Reported growth (%)
Electrophysiology5,2675,6347.0
Abiomed1,4961,75117.1
Shockwave5641,146—
Other Cardiovascular3803974.3
Orthopaedics sub-franchise (USD Mn)FY2024FY2025Reported growth (%)
Hips1,6381,6742.1
Knees1,5451,5872.7
Trauma3,0493,1463.2
Spine, Sports & Other2,9262,852-2.5
Vision sub-franchise (USD Mn)FY2024FY2025Reported growth (%)
Contact Lenses / Other3,7333,9104.8
Surgical1,4131,55810.2

Cardiovascular. The Biosense Webster electrophysiology platform comprises the CARTO 3 mapping system (with CARTOSOUND SONATA debuted at HRS 2026), the THERMOCOOL SMARTTOUCH SF radiofrequency ablation catheter family — including a Dual Energy version approved by FDA in Q2 2026 and CE-marked earlier — and the VARIPULSE pulsed-field ablation platform, used to treat more than 40,000 atrial fibrillation patients, with VARIPULSE Pro approved in Europe in Q1 2026 carrying a pulse sequence five times faster. The investigational OMNYPULSE catheter reported positive three-month data. A landmark head-to-head pulsed-field ablation trial in persistent atrial fibrillation was launched in Q2 2026. Abiomed supplies the Impella family of percutaneous heart pumps (Impella CP, Impella 5.5 with SmartAssist, Impella RP) for cardiogenic shock and high-risk PCI. Shockwave supplies intravascular lithotripsy catheters for calcified coronary and peripheral artery disease, with the C2 Aero coronary IVL catheter launched globally in Q2 2026. Neurovascular products address stroke and related conditions, including the TRUFILL n-BCA Liquid Embolic System, FDA-approved in Q4 2025 for symptomatic chronic subdural hematoma.

Surgery. The Ethicon portfolio spans endocutters and stapling (including the ETHICON 4000 Stapler, launched in 2025 and CE-marked in Q2 2026), advanced energy devices, wound closure (the principal growth driver in fiscal 2025 and H1 2026), biosurgery (including ETHIZIA, anticipated for approval in 2026), and open, laparoscopic and robotic instrumentation. OTTAVA, the world's first table-integrated soft-tissue robotic surgical system, received FDA De Novo authorization on 22 July 2026 for multiple general-surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. Mentor supplies breast aesthetics and reconstruction products.

Orthopaedics (DePuy Synthes). Hip and knee reconstruction (ATTUNE knee system; the VELYS Robotic-Assisted Solution driving knee pull-through), trauma fixation (the largest single Orthopaedics platform at USD 3.1 billion), spine, sports medicine and shoulders. A two-year restructuring exiting selected markets and product lines was substantially completed in Q4 2025. In Q2 2026 DePuy Synthes agreed to acquire miniature radiofrequency tracking technology for its joint reconstruction portfolio and entered an exclusive U.S., Canada and Australia distribution agreement for CGBIO's NOVOSIS bone graft product.

Vision. The ACUVUE contact lens family, including the ACUVUE OASYS 1-Day franchise and the ACUVUE OASYS MAX 1-Day line extended in 2025 to astigmatism and presbyopia. The TECNIS premium intraocular lens range for cataract surgery, including TECNIS Odyssey — described by the company as the fastest-growing IOL in the U.S. — and TECNIS PureSee, approved for U.S. cataract patients in Q1 2026 with availability expanded in Q2 2026. More than USD 1 billion has been committed to strengthen U.S. vision manufacturing in Jacksonville, Florida.

Pricing model. The company does not disclose product-level pricing. Innovative Medicine pricing is realised net of rebates, returns and promotional allowances — accrued rebates, returns and promotions on the balance sheet grew from USD 12,095 million in 2021 to USD 19,124 million in 2025, a 58% increase against 20% revenue growth on an as-reported basis, which is a direct measure of intensifying gross-to-net pressure. Consolidated price contributed −3.1% to fiscal 2025 revenue growth against +8.4% from volume.

Financial Narrative

Basis of presentation. FY2021 and FY2022 are presented as originally reported in the respective Form 10-K filings and therefore include the Consumer Health business; FY2023 onward reflect continuing operations. Restated continuing-operations net sales were USD 78,738 million (FY2021) and USD 79,990 million (FY2022).

Income statement: notes and sources

Depreciation and amortisation for FY2021 and FY2022 is derived from disclosed segment-level D&A reconciled to the disclosed consolidated range and should be treated as approximate; FY2023–FY2025 are as reported in the consolidated statement of cash flows. Other income/(expense), net for FY2021–FY2023 is derived from disclosed common-size percentages applied to reported sales.

Per-share data: notes and sources

Weighted average diluted shares for FY2021–FY2023 are approximate, derived from reported net earnings and EPS; FY2024 and FY2025 (2,429.4 million in both years) are as disclosed.

Margin analysis

Revenue CAGR FY2021–FY2025: 4.6% on the continuing-operations basis; 0.1% on the as-reported basis (the difference is the Kenvue separation).

Commentary on trends and inflections.

Gross margin: The 120 basis-point contraction in fiscal 2025 to 67.9% reflects three converging pressures: adverse mix as high-margin STELARA revenue is replaced by lower-margin or newly launched products; the growing weight of MedTech, which carries a structurally lower gross margin; and unfavourable currency in cost of products sold. Cost of products sold rose 10.1% against 6.0% revenue growth. This is the single most important operating metric to monitor, because the entire double-digit-growth thesis assumes mix improves rather than deteriorates as launches scale.

Operating margin: The 340 basis-point expansion in fiscal 2025 to 26.8% is almost entirely an R&D artefact. R&D fell 14.9% year over year, from USD 17,232 million to USD 14,665 million, because fiscal 2024 carried the USD 1.25 billion Yellow Jersey acquired-IPR&D charge and other one-off programme costs. Normalising for that, underlying R&D spend was broadly flat and operating leverage was modest. Management has guided fiscal 2026 to approximately 75 basis points of adjusted pre-tax operating margin expansion, raised from at least 50 basis points at the Q1 2026 update.

Below the operating line: The fiscal 2025 pre-tax result is dominated by a single item: other income of USD 7,209 million, driven by the approximately USD 7.0 billion talc reserve reversal recorded in Q1 2025. Fiscal 2024's other expense of USD 4,694 million was driven by approximately USD 5.1 billion of talc charges and a USD 0.4 billion loss on the Kenvue share exchange. On a GAAP basis, therefore, the 90.6% growth in fiscal 2025 net earnings is not an operating outcome. The adjusted series is the appropriate comparison: adjusted net earnings grew 8.1% to USD 26,215 million and adjusted diluted EPS grew 8.1% to USD 10.79.

Interest: Net interest has swung from a USD 577 million net income position in fiscal 2024 to a USD 85 million net income position in fiscal 2025 as cash balances were deployed into acquisitions and gross debt was increased. Interest expense has risen more than fivefold since fiscal 2021, from approximately USD 188 million to USD 970 million.

Tax: The effective rate has normalised upward from an anomalously low 8.3% in fiscal 2021 to 17.7% in fiscal 2025, converging with the adjusted effective rate of 17.3%. Q4 2025 carried a negative 3.0% GAAP effective rate on discrete tax items.

Balance sheet: notes and sources

Marketable securities for FY2023 and FY2024, and inventories and goodwill for FY2021–FY2024, are derived from disclosed aggregates and narrative disclosure and should be verified against the source filings before use in a valuation model. Cash and cash equivalents, current assets, all liability lines, equity and total assets are as reported. Net debt is computed as total debt less cash and cash equivalents only; including marketable securities, net debt was approximately USD 2.1 billion in FY2021 and approximately USD 27.8 billion in FY2025.

Cash flow: notes and sources

FY2022 capex is derived from disclosed free cash flow and operating cash flow and is approximate. FY2021 and FY2023 acquisitions net of cash acquired were immaterial or nil as disclosed.

Commentary. Operating cash flow has been remarkably stable in a narrow USD 21.2–24.5 billion band across five years, which is the most persuasive single fact about the durability of the underlying business. Free cash flow has been equally stable at USD 17.2–19.8 billion. What has changed radically is the use of that cash. Between fiscal 2021 and fiscal 2025 the company shifted from a net-cash-accumulating posture (net debt of approximately USD 2 billion including marketable securities at year-end 2021) to a net-debt position of approximately USD 28 billion, with USD 49.9 billion deployed on acquisitions across 2022, 2024 and 2025 alone. Dividends have grown steadily but modestly (12.2% cumulative over four years), while buybacks have been episodic, ranging from USD 2.4 billion to USD 6.0 billion annually with no fixed authorisation disclosed as outstanding at year-end 2025.

Fiscal 2025 free cash flow conversion — free cash flow of USD 19,698 million against adjusted net earnings of USD 26,215 million — was 75%, a level that reflects both elevated capital expenditure (USD 4.8 billion, the highest in the period, tracking the USD 55 billion U.S. investment programme) and a USD 5.7 billion working-capital drag from the decrease in other current and non-current liabilities, which is consistent with talc-related cash outflows.

H1 2026 free cash flow was approximately USD 8,700 million, up from USD 6,214 million in H1 2025.

Ratio analysis

Return on equity and return on assets for FY2023 are inflated by the USD 21.0 billion Kenvue separation gain and are not comparable. Return on invested capital is computed as after-tax operating earnings divided by year-end total debt plus shareholders' equity; the trend — a 380 basis-point decline from fiscal 2021 to fiscal 2025 — is the cleanest quantitative summary of the acquisition-intensity question, and is best read alongside the goodwill-and-intangibles ratio, which reached 49.8% of total assets at year-end 2025.

Cash conversion cycle. Approximate FY2025 values: days inventory outstanding approximately 171 days; days sales outstanding approximately 66 days; days payables outstanding approximately 145 days; cash conversion cycle approximately 92 days. These are derived using estimated year-end trade receivables and should be confirmed against the FY2025 balance sheet detail. Inventory days have risen materially since fiscal 2021, consistent with the disclosed increase in inventories from USD 10.4 billion to USD 14.2 billion.

Fiscal 2026 interim performance: notes and sources

H1 2026 pre-tax earnings of USD 12.7 billion (25.8% of sales) compare with USD 20.1 billion (44.1%) in H1 2025, the difference being the prior-year USD 7.0 billion talc reversal. Q1 2026 operating cash flow was USD 2,514 million; dividends paid USD 3,131 million; share repurchases USD 4,028 million; cash and equivalents USD 21,688 million at 29 March 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (USD Mn)FY2023FY2024FY2025

Innovative Medicine

54,75956,96460,401

MedTech

30,40031,85733,792

Total company

85,15988,82194,193

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of total revenue (%)

Segment share of total revenue (%)FY2023FY2024FY2025

Innovative Medicine

64.364.164.1

MedTech

35.735.935.9

Segment YoY reported growth (%)

Segment YoY reported growth (%)FY2023FY2024FY2025

Innovative Medicine

-18.94.06.0

MedTech

10.84.86.1

Segment income before tax (USD Mn)

Segment income before tax (USD Mn)FY2023FY2024FY2025

Innovative Medicine

18,24618,91922,266

MedTech

4,6693,7404,113

Segment earnings before tax

22,91522,65926,379

Income/(expenses) not allocated to segments

-7,8505,972-6,202

Worldwide income before tax

15,06516,68732,581

Segment pre-tax margin (%)

Segment pre-tax margin (%)FY2023FY2024FY2025

Innovative Medicine

33.333.236.9

MedTech

15.411.712.2

Combined segment margin

26.925.528.0

Segment Assets & Liabilities and Revenue by Segment

Innovative Medicine (USD Mn)FY2021FY2022FY2023FY2024FY2025

Identifiable assets

89,45782,50458,32457,07078,057

Additions to property, plant & equipment

1,5291,6971,6531,7102,076

Depreciation and amortisation

4,7884,5503,8473,7603,772

Segment Assets & Liabilities and Revenue by Segment by MedTech

MedTech (USD Mn)FY2021FY2022FY2023FY2024FY2025

Identifiable assets

53,37270,95674,71084,32286,482

Additions to property, plant & equipment

1,9332,1202,3722,4432,501

Depreciation and amortisation

2,2862,3022,9433,2373,490

Income Statement

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Net sales to customers (as reported)

93,77594,94385,15988,82194,193

Net sales, continuing operations basis

78,73879,99085,15988,82194,193

Cost of products sold

29,85531,08926,55627,47130,256

Gross profit

63,92063,85458,60361,35063,937

Selling, marketing and administrative expenses

24,66324,76121,51022,86923,676

Research and development expense

14,71414,60015,08517,23214,665

In-process R&D impairments

90078131621181

Restructuring

252322491234228

Operating earnings

23,39123,39021,20120,80425,287

Depreciation and amortisation

7,3976,9707,4867,3397,503

EBITDA

30,78830,36028,68728,14332,790

Interest expense

188275775755970

Other income/(expense), net

-488-1,870-6,634-4,6947,209

Earnings before provision for taxes

22,77721,72515,06516,68732,581

Provision for taxes on income

1,8903,7841,7362,6215,777

Net earnings from continuing operations

20,87817,94113,32914,06626,804

Net earnings from discontinued operations

0021,82400

Net earnings

20,87817,94135,15314,06626,804

Adjusted net earnings (non-GAAP)

00024,24226,215

Per-Share Data and Share Count (M)

Metric (USD)FY2021FY2022FY2023FY2024FY2025

Diluted EPS (total)

7.816.7313.835.7911.03

Diluted EPS, continuing operations

7.816.735.205.7911.03

Adjusted diluted EPS (non-GAAP)

0.000.000.009.9810.79

Dividends declared per share

4.194.454.704.915.14

Weighted average diluted shares (M)

2,6742,6652,5422,4292,429

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

68.267.368.869.167.9

Operating margin

24.924.624.923.426.8

EBITDA margin

32.832.033.731.734.8

Pre-tax margin

24.322.917.718.834.6

Net margin

22.318.941.315.828.5

Effective tax rate

8.317.411.515.717.7

R&D as % of sales

15.715.417.719.415.6

SM&A as % of sales

26.326.125.325.725.1

Balance Sheet

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Cash and cash equivalents

14,48714,12721,85924,10519,709

Marketable securities

17,1219,3921,0001,180393

Inventories

10,38712,48311,18112,65314,191

Current assets

60,97955,29453,49555,89355,624

Property, plant and equipment, net

18,96219,44220,56721,79823,169

Intangible assets, net

46,39248,24334,17543,27250,403

Goodwill

35,24645,23136,55838,54648,772

Non-current assets

121,039132,084114,063124,211143,586

Total assets

182,018187,378167,558180,104199,210

Loans and notes payable (short-term debt)

3,76612,7713,4515,9838,495

Accounts payable

11,05511,7039,63210,31111,991

Accrued rebates, returns and promotions

12,09514,41716,00117,58019,124

Current liabilities

45,22655,80246,28250,32154,126

Long-term debt, excluding current portion

29,98526,88825,88130,65139,438

Non-current liabilities

62,76954,77252,50258,29363,540

Total liabilities

107,995110,57498,784108,614117,666

Shareholders' equity

74,02376,80468,77471,49081,544

Total debt

33,75139,65929,33236,63447,933

Net debt (total debt less cash)

19,26425,5327,47312,52928,224

Goodwill and intangibles combined

81,63873,47470,73381,81899,175

Working capital

15,753-5087,2135,5721,498

Cash Flow

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Net cash from operating activities

23,41021,19422,79124,26624,530

Additions to property, plant and equipment (capex)

3,6524,0094,5434,4244,832

Free cash flow

19,75817,18518,24819,84219,698

Acquisitions, net of cash acquired

017,200015,14617,541

Dividends paid to shareholders

11,03211,68211,77011,82312,381

Repurchase of common stock

3,4566,0355,0542,4075,953

Net cash used by investing activities

0-12,371878-18,599-23,588

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

Return on equity (%)

28.223.451.119.732.9

Return on assets (%)

11.59.621.07.813.5

Return on invested capital (%)

19.916.619.116.216.1

Current ratio (x)

1.350.991.161.111.03

Debt to equity (x)

0.460.520.430.510.59

Net debt to EBITDA (x)

0.630.840.260.450.86

Interest coverage (EBIT/interest expense, x)

12485272826

Total asset turnover (x)

0.520.510.510.490.47

Goodwill and intangibles as % of total assets

44.939.242.245.449.8

Key Financials and Margin Analysis (%)

Metric (USD Mn unless noted)Q1 2026Q2 2026H1 2026

Reported sales

24,06225,31049,372

Reported sales growth (%)

9.96.68.2

Operational sales growth (%)

6.45.60.0

Innovative Medicine sales

016,3840

MedTech sales

08,9260

Net earnings

5,2355,5340

Diluted EPS (USD)

2.142.270.00

Adjusted diluted EPS (USD)

2.702.900.00

Earnings before taxes

06,70012,700

Revenue by Region

Region (USD Mn)FY2024FY2025

United States

50,30253,752

Europe

20,21221,535

Western Hemisphere excluding U.S.

4,7144,875

Asia-Pacific, Africa

13,59314,031

International total

38,51940,441

Worldwide

88,82194,193

Region growth FY2025 (%)

Region growth FY2025 (%)ReportedOperationalCurrency

United States

6.96.90.0

Europe

6.52.44.1

Western Hemisphere excluding U.S.

3.48.4-5.0

Asia-Pacific, Africa

3.23.10.1

International total

5.03.41.6

Worldwide

6.05.30.7

Region share of total revenue (%)

Region share of total revenue (%)FY2024FY2025

United States

56.657.1

Europe

22.822.9

Western Hemisphere excluding U.S.

5.35.2

Asia-Pacific, Africa

15.314.9

Revenue by Region by Segment × Geography

Segment × geography (USD Mn)FY2024FY2025

Innovative Medicine — United States

33,97036,344

Innovative Medicine — International

22,99424,057

MedTech — United States

16,33217,408

MedTech — International

15,52516,384

Segment × geography growth FY2025 (%)

Segment × geography growth FY2025 (%)ReportedOperational

Innovative Medicine — United States

7.07.0

Innovative Medicine — International

4.62.9

MedTech — United States

6.66.6

MedTech — International

5.54.1

Valuation Snapshot

MetricValue

Share price (7 Aug 2026 close)

USD 259.24

Market capitalisation

Approximately USD 625 billion

Total return, fiscal 2025

47.5% (share price appreciation of 43% plus dividends) — described by management as among the best annual returns in 82 years as a public company

One-year share price change (to early Aug 2026)

+53.0%

Three-year share price change

+60.7%

Five-year share price change

+68.9%

Year-to-date 2026 share price change

+22.9%

Consecutive years of increases

64 (as of 2026); 63 as of the fiscal 2025 report

Q1 2026 quarterly dividend

USD 1.30 per share

Q2 2026 quarterly dividend

USD 1.34 per share

Q3 2026 declared dividend

USD 1.34 per share, ex-date 25 August 2026

Annualised rate

USD 5.36 per share

FY2025 dividends declared per share

USD 5.14

FY2025 dividends paid

USD 12,381 million

Payout of free cash flow

63%

Payout of adjusted net earnings

47%

Valuation Snapshot by Multiple

MultipleValueBasis

P/E, trailing GAAP

23.5x

USD 259.24 / FY2025 diluted EPS of USD 11.03

P/E, trailing adjusted

24.0x

USD 259.24 / FY2025 adjusted diluted EPS of USD 10.79

P/E, forward adjusted

23.5x

USD 259.24 / FY2026 guided adjusted EPS midpoint of approximately USD 11.04 (post-Firefly/Sail)

EV / Sales

6.9x

EV of approximately USD 653bn / FY2025 sales of USD 94.2bn

EV / EBITDA

19.9x

EV of approximately USD 653bn / FY2025 EBITDA of USD 32.8bn. A third-party data provider cites 19.4x, a difference attributable to EBITDA definition

Price / Book

7.7x

USD 625bn market capitalisation / USD 81.5bn shareholders' equity

Free cash flow yield

3.1%

Per third-party data as of August 2026

Dividend yield

2.07%

Annualised USD 5.36 / USD 259.24

Source Details

SourceCoverageConsensus ratingTwelve-month target (USD)

Provider A

23 analysts

Buy

272.50

Provider B

24 analysts (11 Buy, 13 Hold, 0 Sell)

Hold

257.50

Provider C

Not specified

—267.48

Individual recent actions

——

Guggenheim raised to 287 (Aug 2026); Argus raised to 300 (Aug 2026); a Buy rating with a 305 target was the most recent cited as of early August 2026; a bullish 294 target was also noted

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Repurchase of common stock (USD Mn)

3,4566,0355,0542,4075,953

Credit Ratings

AgencyLong-term ratingShort-term ratingOutlookDate

Moody's Ratings

Aaa

Prime-1

Stable

Reaffirmed in periodic review, 2025; new senior notes assigned Aaa

S&P Global Ratings

AAA

—

Stable

Affirmed 24 January 2026; removed from CreditWatch negative and affirmed with stable outlook 25 April 2025

Analyst Conclusions

Management guidance

MetricRangeMidpointGrowth vs. FY2025
Estimated reported sales (USD bn)100.8 – 101.4101.17.3%
Operational sales (USD bn)100.3 – 100.9100.66.8%
Adjusted operational sales growth6.2% – 6.8%6.5%—
Adjusted EPS (USD)Revised down by 0.64Approximately 11.042.3%
Adjusted operational EPS (USD)Revised down by 0.64Approximately 10.94Approximately 1.4%
Adjusted pre-tax operating margin—Approximately +75 bpsRaised from at least +50 bps

For fiscal 2026, following the 29 July 2026 revision for the Firefly and Sail transactions:

Guidance is calculated at a euro average rate of USD 1.15. Fiscal 2026 contains a 53rd week, weighting Q4. Beyond 2026, management has consistently reaffirmed a line of sight to double-digit revenue growth by the end of the decade. The next scheduled forum for medium-term targets is the Enterprise Business Review on 8 December 2026.

Consensus expectations

Consensus is clustered around the guided sales figure of roughly USD 101 billion for 2026, with EPS estimates in the process of resetting following the 29 July guidance revision. The twelve-month price target range across providers is USD 257.50 to USD 305, with the most commonly cited averages at USD 267–273. Rating distribution is approximately 11 Buy, 13 Hold and 0 Sell — a Hold-leaning consensus at the stock's current level after a 53% twelve-month advance.

Bull case

1. The talc discount unwinds. For a decade the market has applied a valuation discount for an unquantifiable liability. A USD 5.5 billion settlement — against a company generating USD 19.7 billion of annual free cash flow and holding Aaa/AAA ratings — converts an unbounded tail risk into a defined, affordable cash obligation. If the 95% acceptance threshold is met and the settlement finalises, the discount should compress. The June 2026 expert-withdrawal ruling materially improved the company's negotiating position, which is why the settlement multiple is well below the USD 8–10 billion previously contemplated in bankruptcy.

2. The 2029 inflection is real and mechanically driven. Three separable effects converge at the end of the decade: the Genmab DARZALEX royalty of 12–20% (USD 2.4 billion in fiscal 2025) rolls off; STELARA's erosion fully annualises out of the growth base, removing what was a 1,040 basis-point drag in fiscal 2025; and the 2024–2026 launch cohort — TREMFYA in IBD, CARVYKTI, RYBREVANT FASPRO, CAPLYTA, ICOTYDE, INLEXZO, IMAAVY — scales. Excluding STELARA, the company already grew 11.5% operationally in fiscal 2025. Management's double-digit claim is arithmetic, not aspiration.

3. Portfolio surgery lifts the multiple. Removing a USD 9.3 billion business growing 1.1% at a below-segment margin mechanically raises both group growth and MedTech margin. If a sale at above USD 20 billion materialises rather than a spin, the company converts a low-return asset into deployable capital at a valuation the public market has never awarded it inside the conglomerate. Sell-side commentary has begun describing the company as the cleanest growth story in large-cap healthcare on precisely this basis.

Bear case

1. The 2026 EPS guidance cut reveals the cost of the growth story. Adjusted EPS growth for 2026 fell from 8.2% to 2.3% in a single announcement because of two transactions totalling less than USD 1.8 billion of committed cash. The fiscal 2027 dilution is guided at approximately USD 1.36 — more than 12% of the current EPS base. If the double-digit-growth ambition requires a continuous stream of such deals, reported earnings growth will remain structurally suppressed, and the company will be asking investors to underwrite platform bets (in vivo CAR-T, degrader antibody conjugates) that are years from revenue.

2. MedTech has not earned its capital and the fix is partial. Segment identifiable assets grew 62% since fiscal 2021 while segment return on assets fell from 8.19% to 4.76% and pre-tax margin from 16.2% to 12.2%. Orthopaedics removal addresses the slowest-growing piece but not the underlying issue, which is that Abiomed and Shockwave were bought at prices requiring sustained high growth to earn a return, in categories — pulsed field ablation especially — where Boston Scientific and Medtronic are competing aggressively. Group return on invested capital has fallen 380 basis points in four years, and goodwill and intangibles now represent 49.8% of total assets.

3. U.S. pricing is a one-way structural compression that the company has now contractually accepted. Price contributed −3.1% to fiscal 2025 revenue growth. Accrued rebates, returns and promotions rose 58% since fiscal 2021 against 20% as-reported revenue growth. The January 2026 MFN agreement commits to aligning U.S. prices with comparable developed markets for cash-paying patients and Medicaid; ERLEADA joins the Selected Drug list for 2028; Part D redesign shifts costs to manufacturers. The tariff exemption obtained in exchange is valuable but does not extend to MedTech, which faces approximately USD 500 million of tariff cost in 2026. Gross margin has already contracted 120 basis points.

Catalysts and monitorables — next twelve months

CatalystExpected timingWhy it matters
Talc settlement claimant acceptance reaching 95%H2 2026 into 2027Binary determinant of whether the settlement takes effect
UK talc group action progressOngoingThe largest excluded exposure
Enterprise Business Review8 December 2026Medium-term targets; likely the forum for a formal double-digit-growth framework and post-Orthopaedics segment guidance
Orthopaedics separation structure decisionH2 2026Spin versus sale determines whether the company receives cash proceeds; a sale above USD 20bn would be materially more valuable
Q3 2026 resultsOctober 2026First quarter including the USD 1bn Firefly IPR&D charge; first read on ICOTYDE scripts at scale
ICOTYDE prescription trajectoryOngoing quarterlyThe single most important new-product datapoint; determines whether the oral IL-23 thesis is validated
OTTAVA commercial launch and placementsH2 2026 into 2027First evidence on whether a late entrant can take soft-tissue robotics share
IMAAVY wAIHA approval decisionUnder Priority ReviewWould create a first-in-disease franchise
STELARA erosion rateQuarterlyDetermines when the growth drag annualises out
Q4 2026 results and FY2027 guidanceJanuary 2027First guidance incorporating the full Sail dilution and, potentially, Orthopaedics as discontinued operations
Credit rating reviewsOngoingWatch adjusted leverage against the 1.0x threshold given elevated buybacks and continued M&A
Leadership transition execution under Tom CavanaughFrom 1 September 2026Continuity at 64% of revenue

Analyst verdict

Johnson & Johnson enters the second half of 2026 in the strongest strategic position it has occupied in a decade, and simultaneously at the point of maximum expectation. The bull and bear cases are not, in fact, in disagreement about the facts; they disagree about what the market has already paid for.

The facts are these. The company will exceed USD 100 billion of revenue for the first time in 2026. It has resolved, subject to a 95% acceptance threshold, the litigation that has defined it externally since 2016, at a cost of roughly one quarter of one year's free cash flow. It has assembled — through USD 50 billion of acquisitions since 2022 — genuine category leadership in cardiovascular intervention and a credibly renewed pipeline in oncology, immunology and neuroscience. It retains a balance sheet that only two other U.S. corporations can match. And it has an identifiable, mechanically driven earnings inflection at the end of the decade as the Genmab royalty rolls off and STELARA's drag annualises out.

The counterweight is that the shares have already advanced 53% in twelve months and 22.9% year to date, taking the multiple to roughly 23.5x forward adjusted earnings for a business guiding to 2.3% adjusted EPS growth in 2026. The July 2026 guidance revision was the market's first clear look at the price of the growth ambition: two modest transactions cost 5.9 percentage points of guided EPS growth in a single announcement, and 2027 dilution is guided at more than 12% of the current earnings base. Meanwhile the two metrics that measure whether capital deployment is working — MedTech return on assets at 4.76% and group return on invested capital down 380 basis points since 2021 — are both moving the wrong way, and goodwill and intangibles now represent almost half of total assets.

The reasonable central case is that the double-digit-growth ambition is achievable but arrives later and lumpier than the narrative implies, and that between now and 2029 the company delivers mid-single-digit revenue growth with adjusted EPS growth suppressed by continued platform acquisition. In that scenario the shares are approximately fairly valued at current levels, which is precisely what the 13-Hold, 11-Buy, 0-Sell consensus distribution and the USD 257.50 low-consensus target are saying.

The asymmetry sits in two places. On the upside, an Orthopaedics sale above USD 20 billion rather than a spin-off would convert a persistently low-return asset into deployable capital at a valuation never awarded inside the conglomerate, and would be a genuine positive surprise. On the downside, failure to reach the 95% talc acceptance threshold would reopen an exposure the market has begun to treat as closed. Both are decidable within twelve months, and the 8 December 2026 Enterprise Business Review is the moment management must convert a repeated verbal ambition into a numbered plan. Until then, the appropriate posture is constructive on the business and disciplined on the entry price.


End of dossier.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameAgeTitleAppointed to ECPrior background

Joaquin Duato

63

Chairman of the Board; Chief Executive Officer

2016

Joined the company 1989 at Janssen-Farmaceutica S.A. (Spain); EVP Worldwide Chairman Pharmaceuticals from 2016; Vice Chairman of the Executive Committee; CEO and Director from 2022; Chairman from 2023

Joseph J. Wolk

59

EVP, Chief Financial Officer

2018

Joined 1998 as Finance Manager, Business Development, Ortho-McNeil; CFO of the Janssen Pharmaceutical Companies; VP Investor Relations

Jennifer L. Taubert

62

EVP, Worldwide Chairman, Innovative Medicine

2018

Joined 2005; Company Group Chairman North America and then The Americas, 2012–2018. Retiring effective 1 September 2026

Tom Cavanaugh

—

EVP, Worldwide Chairman, Innovative Medicine (effective 1 September 2026)

2026

Joined 2017; senior roles in Oncology, Immunology and Global Commercial Strategy; most recently Company Group Chairman, North America, Innovative Medicine; nearly 15 years at Celgene prior

Tim Schmid

56

EVP, Worldwide Chairman, MedTech

2023

Joined 1993; Chief Strategic Customer Officer; President of Ethicon; Company Group Chairman MedTech Asia Pacific 2018–2023

John C. Reed, M.D., Ph.D.

67

EVP, Innovative Medicine, R&D

2023

Joined 2023; executive leadership at Sanofi (2018–2022) and Roche (2013–2018), on both executive committees; CEO of Sanford-Burnham Medical Research Institute

Kathryn E. Wengel

60

EVP, Chief Technical Operations & Risk Officer

2018

Joined 1988 as Project Engineer at Janssen; EVP Chief Global Supply Chain Officer from 2018; roles across operations, quality, engineering, new products and IT

James Swanson

60

EVP, Chief Information Officer

2022

Rejoined 2019 from Bayer Crop Science (CIO and Head of Digital Transformation); at the company 1996–2005 in roles up to VP, CIO

Elizabeth Forminard

55

EVP, Chief Legal Officer

2022

Joined 2006; General Counsel Medical Devices & Diagnostics; General Counsel Consumer Group & Supply Chain; WW VP Corporate Governance; General Counsel Pharmaceuticals

Kristen Mulholland

59

EVP, Chief Human Resources Officer

2024

Joined 2005; HR leadership across MedTech, Innovative Medicines, Corporate Functions and Global Total Rewards

Vanessa Broadhurst

57

EVP, Global Corporate Affairs

2022

Rejoined 2017; Company Group Chairman, Global Commercial Strategy Organization from 2018; General Manager roles at Amgen 2013–2017; at the company 2005–2013

“—” = not publicly disclosed.

Board of Directors

DirectorPrincipal affiliation

Joaquin Duato

Chairman of the Board and CEO, Johnson & Johnson

Marillyn A. Hewson

Former Chairman and CEO, Lockheed Martin Corporation — Lead Independent Director

Mary C. Beckerle

Distinguished Professor of Biology & Oncological Sciences, University of Utah

Jennifer A. Doudna

Principal Investigator, Doudna Lab; Professor of Biochemistry, Biophysics and Structural Biology, University of California, Berkeley

Paula A. Johnson

President, Wellesley College

Hubert Joly

Former Chairman and CEO, Best Buy Co., Inc.

Mark B. McClellan

Director, Duke-Robert J. Margolis, MD, Center for Health Policy, Duke University

John G. Morikis

Former Executive Chairman and CEO, The Sherwin-Williams Company

Daniel E. Pinto

Vice Chairman, JPMorganChase

Mark A. Weinberger

Former Global Chairman and CEO, Ernst & Young — Regulatory Compliance & Sustainability Committee Chair

Nadja Y. West

Former Lieutenant General, U.S. Army

Eugene A. Woods

Healthcare system executive

Directors' Remuneration

ExecutiveSalary (USD Mn)Annual incentive (USD Mn)Long-term incentive (USD Mn)Total direct compensation (USD Mn)

Joaquin Duato, Chairman and CEO

1.63.522.027.1

Joseph J. Wolk, EVP and CFO

1.21.89.012.1

Jennifer L. Taubert, EVP Innovative Medicine

1.21.89.212.2

John C. Reed, EVP Innovative Medicine R&D

1.21.88.311.3

Tim Schmid, EVP MedTech

0.91.45.98.3

Major Shareholders

HolderShares (M)Approximate stake (%)

The Vanguard Group, Inc.

236.09.8

State Street Global Advisors

132.85.5

BlackRock, Inc.

129.85.4

Geode Capital Management

60.62.5

JPMorgan Asset Management

36.71.5

Norges Bank Investment Management

31.91.3

State Farm Insurance (asset management arm)

31.71.3

Northern Trust Global Investments

30.91.3

Morgan Stanley Investment Management

30.21.3

UBS Asset Management AG

28.31.2

Competitive Landscape

Peer Comparison FY2025

MetricJohnson & JohnsonMerck & Co.PfizerAbbVie

Total revenue (USD Bn)

94.265.062.661.2

Pharmaceutical-only revenue (USD Bn)

60.465.062.661.2

Revenue growth (%)

6.01.0-1.68.6

Operating income (USD Bn)

25.321.214.215.1

Operating margin (%)

26.832.622.824.7

Net income (USD Bn)

26.818.37.84.2

Net margin (%)

28.528.112.46.9

R&D expense (USD Bn)

14.7

n/v

n/v

n/v

R&D intensity (%)

15.6

n/v

n/v

n/v

Total assets (USD Bn)

199.2136.9208.2134.0

Total equity (USD Bn)

81.552.686.5-3.3

Employees

140,80075,00075,00057,000

Peer Comparison FY2025 — Latest full-year revenue

MetricJ&J MedTechMedtronicAbbott (devices)StrykerBoston Scientific

Latest full-year revenue (USD Bn)

33.836.430.325.120.0

Fiscal period

FY2025 (Dec)

FY2026 (Apr)

FY2025 (Dec)

FY2025 (Dec)

FY2025 (Dec)

Revenue growth (%)

6.18.4

n/v

n/v

19.9

Segment pre-tax margin (%)

12.2

n/v

n/v

n/v

n/v

Recent Developments

--

Company Snapshot

140,800

Employees

$625,000M

Market Cap

2023

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

  • Aaa/AAA credit ratings, held by only three U.S. corporates. Moody's maintains an Aaa senior unsecured long-term rating and a Prime-1 short-term rating with a stable outlook; S&P affirmed AAA with a stable outlook on 24 January 2026, having removed the CreditWatch negative placement on 25 April 2025.
  • Free cash flow stability of USD 17.2–19.8 billion across five fiscal years, through a consumer-health separation, three failed bankruptcy strategies and a USD 4.3 billion loss of STELARA revenue.
  • Portfolio depth of 28 billion-dollar platforms, demonstrated by the fact that excluding STELARA, fiscal 2025 operational growth was 11.5% against 5.3% reported.
  • Innovative Medicine segment pre-tax margin of 36.9% in fiscal 2025, up 360 basis points, on USD 60.4 billion of revenue — a scale-plus-margin combination few peers match.
  • 64 consecutive years of dividend increases, with fiscal 2025 dividends of USD 12,381 million comfortably covered by USD 19,698 million of free cash flow (63% payout of FCF).
  • Demonstrated launch execution. CARVYKTI grew 95.9% to USD 1,887 million; TREMFYA grew 40.5% to USD 5,155 million; CAPLYTA delivered USD 700 million in nine months post-close; Shockwave doubled to USD 1,146 million in its first full year.
  • Governance credibility on incentive design, evidenced by the Board's exclusion of the USD 7 billion talc reversal from 2025 incentive metrics.

Weaknesses

  • Product concentration. DARZALEX at 15.0%, STELARA at 6.5% and TREMFYA at 5.5% of total revenue — approximately 27% from three franchises, with DARZALEX U.S. patents expiring in 2029.
  • MedTech segment pre-tax margin of 12.2%, down from 16.2% in fiscal 2021 despite USD 33.1 billion of asset growth in the segment over the same period.
  • Segment return on assets in MedTech of 4.76%, versus 8.19% in fiscal 2021 — capital deployed has not yet earned its cost.
  • Goodwill and intangibles at 49.8% of total assets (USD 99.2 billion of USD 199.2 billion), the highest level in the five-year period and a rising impairment surface.
  • Gross margin contraction of 120 basis points in fiscal 2025 with cost of products sold growing 10.1% against 6.0% revenue growth.
  • Working capital of only USD 1,498 million and a current ratio of 1.03x at year-end 2025, down from USD 15,753 million and 1.35x in fiscal 2021.
  • Customer concentration: three unnamed wholesalers represent 48.4% of total gross revenues.
  • Interest coverage has fallen from 124x to 26x in four years as gross debt rose from USD 33.8 billion to USD 47.9 billion.

Opportunities

  • ICOTYDE. The first and only oral IL-23 receptor peptide, approved 18 March 2026, with more than 1,500 prescriptions and 1,000 unique prescribers within weeks of launch, and management describing it as potentially one of the company's largest products ever.
  • OTTAVA. FDA De Novo authorization received 22 July 2026 for the world's first table-integrated soft-tissue robot, opening a market where the company currently has effectively no share.
  • Orthopaedics separation. Removing a USD 9.3 billion business growing 1.1% would mechanically lift group growth and MedTech margins; management characterises the intent as accelerating the shift to higher-growth, higher-margin markets.
  • Genmab royalty roll-off from 2029. Eliminating a 12–20% royalty on approximately USD 14.4 billion of DARZALEX sales — USD 2.4 billion in fiscal 2025 — is an explicit component of management's end-of-decade double-digit-growth case.
  • Earlier-line myeloma expansion. MajesTEC-3 supports TECVAYLI plus DARZALEX FASPRO as early as second line, and DARZALEX FASPRO is now approved in smouldering disease, materially expanding the treated population.
  • IMAAVY in warm autoimmune hemolytic anemia, granted Priority Review in Q2 2026 for a disease with no FDA-approved therapies, plus Phase 2 signals in lupus and Sjögren's disease.
  • Talc resolution. A USD 5.5 billion settlement covering the substantial majority of U.S. ovarian cancer claims would remove a decade-long valuation discount if the 95% acceptance threshold is met.
  • Tariff exemption secured for pharmaceutical products under the January 2026 agreement, a cost advantage over non-participating competitors.

Threats

  • STELARA erosion is not finished. The product fell 41.3% to USD 6,078 million in fiscal 2025 and still created a 760 basis-point drag on Innovative Medicine growth in Q2 2026, implying further decline ahead.
  • DARZALEX 2029 patent cliff. At 15.0% of total revenue, this is the single largest identifiable future revenue risk in the portfolio, and biosimilar preparation is already visible in sell-side commentary.
  • Litigation is not fully resolved. The USD 5.5 billion settlement is conditional on 95% claimant acceptance; the UK group action covering more than 7,000 potential claimants is expressly excluded; mesothelioma verdicts continue adversely, including a record USD 1.5 billion award in December 2025 and a USD 65.5 million verdict upheld in June 2026.
  • IRA and MFN pricing. ERLEADA joins the Selected Drug list for 2028; the MFN commitment aligns U.S. cash prices with developed-market benchmarks; price contributed −3.1% to fiscal 2025 growth.
  • MedTech tariffs of approximately USD 500 million expected in 2026, materially above 2025, and not covered by the pharmaceutical exemption.
  • Near-term dilution from platform bets. Firefly and Sail together reduce fiscal 2026 adjusted EPS by USD 0.64 and fiscal 2027 by approximately USD 1.36 — cutting guided 2026 adjusted EPS growth from 8.2% to 2.3%.
  • Leadership transition at the largest segment, with Jennifer Taubert departing 1 September 2026 after eight years leading a business she grew from USD 40.7 billion to more than USD 60 billion.
  • Competitive entry in pulsed field ablation from Boston Scientific and Medtronic, with the company having already acknowledged PFA catheter competitive pressure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Intra-Cellular Therapies acquisition completed (USD 14.6bn)Largest acquisition since Abiomed; rebuilds Neuroscience
Apr 25, 2025S&P affirms AAA and removes CreditWatch negativeResolves the rating risk created by the Intra-Cellular deal
Q1 2025Approximately USD 7.0bn talc reserve reversal recordedDominates fiscal 2025 GAAP earnings; excluded from executive incentive metrics
Aug 2025USD 2bn, ten-year North Carolina manufacturing commitment (Holly Springs)Part of the USD 55bn U.S. programme
Sep 2025Holly Springs biopharmaceutical site secured; approximately 120 jobsU.S. onshoring
Sep 2025INLEXZO approved for BCG-unresponsive high-risk NMIBCNew oncology modality
Oct 14, 2025Q3 2025 results; full-year sales guidance raised to a USD 93.7bn midpointOperational growth of 5.4%
Oct 14, 2025Intent to separate Orthopaedics announced; Namal Nawana appointed Worldwide President of DePuy SynthesThe largest structural decision since Kenvue
Oct 2025UK talc group action filed covering more than 7,000 potential claimantsThe largest product liability case in UK history; not covered by the U.S. settlement
Oct 2025Florida jury awards USD 20m in a talc mesothelioma caseContinued adverse mesothelioma verdicts
Q4 2025Halda Therapeutics acquisition completedReduced Q4 2025 EPS by USD 0.10
Q4 2025FDA approves CAPLYTA for major depressive disorderExpands the largest Neuroscience asset
Q4 2025FDA approves RYBREVANT FASPRO plus LAZCLUZE for NSCLCShortest first-line combination administration time
Q4 2025FDA approves AKEEGA for BRCA2-mutated mCSPCFirst precision therapy in the indication; 54% reduction in progression
Q4 2025DARZALEX FASPRO approved for high-risk smouldering multiple myelomaFirst and only approved therapy in the setting
Q4 2025FDA approves TRUFILL n-BCA for chronic subdural hematomaNeurovascular expansion
Dec 2025MajesTEC-3 results support TECVAYLI plus DARZALEX FASPRO as early as second linePotential standard-of-care shift in myeloma
Dec 2025Janssen seeks U.S. Supreme Court review of the Third Circuit IRA rulingEscalation of the constitutional challenge to Medicare price negotiation
Dec 16, 2025California jury awards USD 40m in two ovarian cancer talc casesPre-settlement verdict pressure
Dec 19, 2025Minnesota jury awards USD 65.5m in a pleural mesothelioma caseFailure-to-warn finding on asbestos contamination
Dec 22, 2025Baltimore jury awards a record USD 1.5bn in a peritoneal mesothelioma caseLargest single talc verdict recorded
Jan 8, 2026Voluntary agreement with the U.S. administration; TrumpRx participation; tariff exemption; two new U.S. manufacturing sitesRemoves a major tariff overhang at the cost of U.S. price realisation
Jan 9, 2026Talc MDL pending claims reported at 68,914, up 9,375 year over year — the largest active MDL in the United StatesScale of the pre-settlement exposure
Jan 2026CMS publishes the 2028 Selected Drug list including ERLEADA; indicates XARELTO and STELARA will be removed from 2027Mixed IRA outcome
Jan 21, 2026FY2025 results; FY2026 guidance at a USD 100.5bn midpointFirst guidance above USD 100bn
Jan 2026OTTAVA submitted to FDARobotic surgery entry
Feb 11, 2026FY2025 Form 10-K filed63 manufacturing facilities; 140,800 employees
Feb 2026Media reports of a potential outright sale of DePuy Synthes above USD 20bnUnconfirmed
Mar 2026Los Angeles court overturns USD 950m of punitive damages in a talc mesothelioma caseRare defence win
Mar 9–11, 20262026 proxy statement filed; CEO total direct compensation of USD 27.1m disclosed; talc reversal excluded from incentive metricsGovernance signal
Mar 18, 2026FDA approves ICOTYDE (icotrokinra)First and only oral IL-23 receptor peptide; potential franchise-defining launch
Apr 14, 2026Q1 2026 results: sales USD 24.1bn, +9.9% reported, +6.4% operational; adjusted EPS USD 2.70; guidance raised to a USD 100.8bn midpointEnterprise Business Review announced for 8 December 2026
Q1 2026VARIPULSE Pro approved in Europe with a pulse sequence five times faster; TECNIS PureSee approved for U.S. cataract patientsMedTech launch cadence
Apr 2026Q1 2026 Form 10-Q filed; USD 3,131m dividends and USD 4,028m buybacks in the quarterElevated capital return
May 2026DePuy Synthes agrees to acquire miniature RF tracking technology; enters NOVOSIS distribution agreementPre-separation portfolio strengthening
Q2 2026FDA approves the Dual Energy THERMOCOOL SMARTTOUCH SF platform; TREMFYA label expansion for structural joint damage; CAPLYTA sNDA for relapse prevention in schizophreniaThree approvals in one quarter
Q2 2026FDA grants Priority Review for IMAAVY in warm autoimmune hemolytic anemiaPotential first approved therapy in the indication
Q2 2026CE Mark for the ETHICON 4000 Stapler; global launch of the Shockwave C2 Aero catheter; more than USD 1bn committed to Jacksonville vision manufacturingMedTech commercial expansion
Jun 8, 2026Agreement to acquire Firefly Bio for USD 1bnDegrader antibody conjugate platform
Jun 17, 2026Company seeks dismissal of thousands of MDL ovarian cancer claims after plaintiffs withdraw two general-causation expertsThe procedural turning point that preceded settlement
Jun 29, 2026Minnesota judge lets the USD 65.5m verdict stand, denying a new trialContinued mesothelioma losses
Jul 15, 2026Q2 2026 results: sales USD 25.3bn, +6.6%; adjusted EPS USD 2.90; guidance raised to a USD 101.1bn midpoint and adjusted EPS of USD 11.68First quarter above USD 25bn
Jul 22, 2026FDA grants De Novo authorization for OTTAVAEntry into the soft-tissue surgical robotics market
Jul 23, 2026Q2 2026 Form 10-Q filedH1 2026 sales USD 49.4bn
Jul 27, 2026Talc settlement of approximately USD 5.5bn announcedPotentially resolves the decade-long overhang
Jul 29, 2026Firefly acquisition completed; Sail Biomedicines collaboration announced; FY2026 adjusted EPS guidance reduced by USD 0.64 to approximately USD 11.04Two-platform bet with material near-term dilution
Aug 3, 2026Investor conference call held on the OTTAVA authorizationManagement signalling the scale of the robotics opportunity
Aug 4, 2026Jennifer Taubert to retire; Tom Cavanaugh appointed EVP, Worldwide Chairman, Innovative Medicine effective 1 September 2026Succession at the largest segment
Aug 2026Guggenheim raises its price target to USD 287 from USD 270; Argus raises to USD 300 from USD 290Sell-side response to the talc resolution

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Net sales to customers rose from USD 93,775 Mn in FY2021 to USD 94,193 Mn in FY2025.
Johnson and Johnson — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Net sales to customers93,77594,94385,15988,82194,193
Net sales, continuing operations basis78,73879,99085,15988,82194,193
Cost of products sold29,85531,08926,55627,47130,256
Gross profit63,92063,85458,60361,35063,937

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.